Literature DB >> 9108405

Strict lymphotropism of Epstein-Barr virus during acute infectious mononucleosis in nonimmunocompromised individuals.

M A Karajannis1, M Hummel, I Anagnostopoulos, H Stein.   

Abstract

Previous investigations of exfoliated oropharyngeal cells from individuals suffering from infectious mononucleosis (IM) suggested that the oropharyngeal epithelia are the primary target and also the site of life-long persistence of the Epstein-Barr virus (EBV). This concept was widely accepted. However, the investigation of histological sections with more sensitive EBV detection techniques has drawn this concept into doubt since EBV proved to be constantly absent in normal epithelial cells. To elucidate the discrepancy, throat washings and peripheral mononuclear blood cells from 16 patients suffering from IM were investigated for EBV-DNA and EBV gene products employing highly sensitive in situ hybridization, immunocytochemistry, and polymerase chain reaction. Although all patients exhibited latently infected B lymphocytes in peripheral blood, samples of exfoliated oropharyngeal cells were constantly EBV-negative with the exception of three cases. In these cases, the patients additionally suffered from purulent ulcerating tonsillitis, EBV-infected B cells, but no EBV-infected epithelial cells were detectable. These findings support the view that recirculating lymphocytes of B-cell origin, but not epithelial cells are the initial target of EBV during primary infection and that B cells also represent the site of life-long viral persistence.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108405

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

2.  Themed issue: the biology and pathology of the Epstein-Barr virus.

Authors:  P G Murray; L S Young
Journal:  Mol Pathol       Date:  2000-10

3.  Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease.

Authors:  I S Misko; S M Cross; R Khanna; S L Elliott; C Schmidt; S J Pye; S L Silins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

4.  Secreted Oral Epithelial Cell Membrane Vesicles Induce Epstein-Barr Virus Reactivation in Latently Infected B Cells.

Authors:  Zhen Lin; Kenneth Swan; Xin Zhang; Subing Cao; Zoe Brett; Stacy Drury; Michael J Strong; Claire Fewell; Adriane Puetter; Xia Wang; MaryBeth Ferris; Deborah E Sullivan; Li Li; Erik K Flemington
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

5.  The infectious kiss: newly infected B cells deliver Epstein-Barr virus to epithelial cells.

Authors:  Georg W Bornkamm; Uta Behrends; Josef Mautner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

6.  CD21-Dependent infection of an epithelial cell line, 293, by Epstein-Barr virus.

Authors:  J D Fingeroth; M E Diamond; D R Sage; J Hayman; J L Yates
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

Review 7.  Molecular virology of Epstein-Barr virus.

Authors:  G W Bornkamm; W Hammerschmidt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

8.  Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell.

Authors:  E M Miyashita; B Yang; G J Babcock; D A Thorley-Lawson
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 9.  Biology and disease associations of Epstein-Barr virus.

Authors:  D H Crawford
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

10.  Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells.

Authors:  Susan E Hoover; Junichi Kawada; Wyndham Wilson; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2008-08-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.